期刊文献+

Effect of ezetimibe on the prevalence of cholelithiasis 被引量:1

Effect of ezetimibe on the prevalence of cholelithiasis
下载PDF
导出
摘要 AIM: To investigate the prevalence of cholelithiasis among patients treated with ezetimibe. METHODS: A retrospective, case-control study based on computerized medical records from patients of the Clalit Health Services, Sharon-Shomron region, from 2000 to 2009. Patients 20-85 years of age, who had been treated with ezetimibe and statins or statins only for at least 6 too, and who had an abdominal ultrasound were included in the study. Collected data included age, gender, ezetimibe treatment duration, presence of hypothyroidism or diabetes, and existence of cholelithiasis as determined by ultrasound. Ex- cluded were subjects after gallbladder resection, with hemolysis, myeloproliferative or inflammatory bowel diseases, and those treated with ursodeoxycholic acid and fibrates. Patients treated with statins and ezeti- mibe (study group) were compared to patients treated with statins only (control group). RESULTS: The study group included 25 patients and the control group 168. All patients in the study were treated with statins. The study group included 13 males (52%) and 12 females (48%), the control group 76 males (45%) and 92 (55%) females (P = 0.544). The groups did not differ in age (mean age: 68 ± 8 years, range 53-85 years vs mean age: 71±8 years, range 51-85 years; P = 0.153) or in the rate of dia- betic and hypothyroid patients [11 (44%) vs 57 (33%), P = 0.347 in the study group and 5 (20%) vs 23 (14%), P = 0.449 in the control group, respectively]. Patients in the study group were treated with ezetimibe for an average of 798±379 d. Cholelithiasis was found in 4 (16%) patients in the study group and in 33 (20%) patients in the control group (P = 0.666). CONCLUSION: Ezetimibe does not appear to influ- ence the prevalence of gallstones. AIM:To investigate the prevalence of cholelithiasis among patients treated with ezetimibe.METHODS:A retrospective,case-control study based on computerized medical records from patients of the Clalit Health Services,Sharon-Shomron region,from 2000 to 2009.Patients 20-85 years of age,who had been treated with ezetimibe and statins or statins only for at least 6 mo,and who had an abdominal ultrasound were included in the study.Collected data included age,gender,ezetimibe treatment duration,presence of hypothyroidism or diabetes,and existence of cholelithiasis as determined by ultrasound.Excluded were subjects after gallbladder resection,with hemolysis,myeloproliferative or inflammatory bowel diseases,and those treated with ursodeoxycholic acid and fibrates.Patients treated with statins and ezetimibe(study group) were compared to patients treated with statins only(control group).RESULTS:The study group included 25 patients and the control group 168.All patients in the study were treated with statins.The study group included 13 males(52%) and 12 females(48%),the control group 76 males(45%) and 92(55%) females(P = 0.544).The groups did not differ in age(mean age:68 ± 8 years,range 53-85 years vs mean age:71 ± 8 years,range 51-85 years;P = 0.153) or in the rate of diabetic and hypothyroid patients [11(44%) vs 57(33%),P = 0.347 in the study group and 5(20%) vs 23(14%),P = 0.449 in the control group,respectively].Patients in the study group were treated with ezetimibe for an average of 798 ± 379 d.Cholelithiasis was found in 4(16%) patients in the study group and in 33(20%) patients in the control group(P = 0.666).CONCLUSION:Ezetimibe does not appear to influence the prevalence of gallstones.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2012年第40期5789-5792,共4页 世界胃肠病学杂志(英文版)
关键词 BILE CHOLESTEROL Neiman-Pick Cl-like Re-ceptor GALLSTONES EZETIMIBE 患病率 胆石症 甲状腺功能减退 他汀类药物 药物治疗 平均年龄 治疗时间 胆囊结石
  • 相关文献

参考文献25

  • 1Attili AF, Carulli N, Roda E, Barbara B, Capocaccia L, Menotti A, Okoliksanyi L, Ricci G, Capocaccia R, Festi D. Epidemiology of gallstone disease in Italy: prevalence data of the Multicenter Italian Study on Cholelithiasis (M.I.COL.). Am J Epidemiol. 1995;141:158-165. [PubMed].
  • 2Sandler RS, Everhart JE, Donowitz M, Adams E, Cronin K, Goodman C, Gemmen E, Shah S, Avdic A, Rubin R. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122:1500-1511. [PubMed] [DOI].
  • 3Strasberg SM. Clinical practice. Acute calculous cholecystitis. N Engl J Med. 2008;358:2804-2811. [PubMed] [DOI].
  • 4Bar-Meir S. Gallstones: prevalence, diagnosis and treatment. Isr Med Assoc J. 2001;3:111-113. [PubMed].
  • 5Portincasa P, Moschetta A, Palasciano G. Cholesterol gallstone disease. Lancet. 2006;368:230-239. [PubMed] [DOI].
  • 6Hui DY, Labonté ED, Howles PN. Development and physiological regulation of intestinal lipid absorption. III. Intestinal transporters and cholesterol absorption. Am J Physiol Gastrointest Liver Physiol. 2008;294:G839-G843. [PubMed] [DOI].
  • 7Lammert F, Miquel JF. Gallstone disease: from genes to evidence-based therapy. J Hepatol. 2008;48 Suppl 1:S124-S135. [PubMed] [DOI].
  • 8Marschall HU, Einarsson C. Gallstone disease. J Intern Med. 2007;261:529-542. [PubMed] [DOI].
  • 9Sudhop T, Lütjohann D, Kodal A, Igel M, Tribble DL, Shah S, Perevozskaya I, von Bergmann K. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 2002;106:1943-1948. [PubMed].
  • 10Davis HR, Basso F, Hoos LM, Tetzloff G, Lally SM, Altmann SW. Cholesterol homeostasis by the intestine: lessons from Niemann-Pick C1 Like 1 [NPC1L1). Atheroscler Suppl. 2008;9:77-81. [PubMed] [DOI].

同被引文献2

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部